Last reviewed · How we verify
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER (SODIUM PHOSPHATE, MONOBASIC ANHYDROUS)
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER (generic name: SODIUM PHOSPHATE, MONOBASIC ANHYDROUS) is a drug developed by OTSUKA ICU MEDCL. It is currently FDA-approved for Constipation.
IONOSOL MB is a small molecule medication, also known as E339, used in a 5% dextrose solution.
At a glance
| Generic name | SODIUM PHOSPHATE, MONOBASIC ANHYDROUS |
|---|---|
| Sponsor | OTSUKA ICU MEDCL |
| Target | Carbonic anhydrase 4 |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Constipation
Common side effects
- Nausea and vomiting
- Dry mouth
- Dizziness
- Blurred vision
- Drowsiness
- Rapid pulse
- Flushing
- Shortness of breath or troubled breathing
- Difficult micturition
- Acute urinary retention
- Urine and stools discoloration (blue to blue-green)
Serious adverse events
- Serious allergic reaction
- Itching
- Rash
- Severe dizziness
- Swelling
- Trouble breathing
Key clinical trials
- Etodalac, Etoricoxib and Dexamethasone for Prevention of Pain ,Swelling and Trismus Following Third Molar Surgery: A Prospective, Double-Blind Study (NA)
- Randomized, Double Blind Comparison Trial of Prolotherapy (Dextrose) Compared to Corticosteroid Injection for the Treatment of Symptomatic Thumb Carpo-metacarpal Joint Arthritis (NA)
- A Single-Dose, Open-Label, Randomized, Parallel-Design Study Of The Comparative Pharmacokinetics And Safety Of TNX-102 2.8 mg SL Tablets (With Potassium Phosphate) At 2.8 mg, TNX-102-B 2.8 mg SL Table (Phase 1)
- Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity (Phase 3)
- Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults (Phase 1)
- The Effectiveness of Intravenous Dexamethasone Prophylaxis in Preventing Post-operative Urinary Retention in Spinal Anesthesia at Al-Makassed Hospital (NA)
- Pain With Trigger Finger Injection: A Comparison of Steroid Alone Versus Steroid/Lidocaine Mixture (Phase 4)
- Comparative Study of the Efficacy of Intravitreal Ranibizumab Versus Its Combination With Commercial Dexamethasone in The Treatment of Diabetic Macular Edema (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER CI brief — competitive landscape report
- IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER updates RSS · CI watch RSS
- OTSUKA ICU MEDCL portfolio CI
Frequently asked questions about IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER
What is IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER?
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER (SODIUM PHOSPHATE, MONOBASIC ANHYDROUS) is a pharmaceutical drug developed by OTSUKA ICU MEDCL, indicated for Constipation.
What is IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER used for?
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER is indicated for Constipation.
Who makes IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER?
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER is developed and marketed by OTSUKA ICU MEDCL (see full OTSUKA ICU MEDCL pipeline at /company/otsuka-icu-medcl).
What is the generic name of IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER?
SODIUM PHOSPHATE, MONOBASIC ANHYDROUS is the generic (nonproprietary) name of IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER.
What development phase is IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER in?
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER is FDA-approved (marketed).
What are the side effects of IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER?
Common side effects of IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER include Nausea and vomiting, Dry mouth, Dizziness, Blurred vision, Drowsiness, Rapid pulse. Serious adverse events: Serious allergic reaction, Itching, Rash, Severe dizziness.
What does IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER target?
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER targets Carbonic anhydrase 4.
Related
- Target: All drugs targeting Carbonic anhydrase 4
- Manufacturer: OTSUKA ICU MEDCL — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Constipation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing